Európska únia - estónčina - EMA (European Medicines Agency)

viatris limited - insuliinglargiin - diabeet mellitus - diabeetis kasutatavad ravimid - suhkurtõve ravi täiskasvanutel, noorukitel ja lastel vanuses 2 aastat ja üle selle.

Európska únia - estónčina - EMA (European Medicines Agency)

eli lilly nederland b.v. - insuliin lispro - diabeet mellitus - diabeetis kasutatavad ravimid - suhkurtõve ravi täiskasvanutel, noorukitel ja 1-aastastel ja vanematel lastel. suhkurtõve ravi täiskasvanutel.

Estónsko - estónčina - Ravimiamet

galenicum health s.l.u. - vildagliptiin - tablett - 50mg 30tk; 50mg 336tk; 50mg 90tk; 50mg 112tk; 50mg 180tk; 50mg 60tk

Európska únia - estónčina - EMA (European Medicines Agency)

novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Európska únia - estónčina - EMA (European Medicines Agency)

novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).

Európska únia - estónčina - EMA (European Medicines Agency)

novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).

Estónsko - estónčina - Ravimiamet

pfizer europe ma eeig - glipisiid - toimeainet prolongeeritult vabastav tablett - 5mg 30tk

Estónsko - estónčina - Ravimiamet

pfizer europe ma eeig - glipisiid - toimeainet prolongeeritult vabastav tablett - 10mg 30tk

Estónsko - estónčina - Ravimiamet

gp-pharm s.a. - oktreotiid - süstelahus - 100mcg 1ml 1ml 5tk

Estónsko - estónčina - Ravimiamet

gp-pharm s.a. - oktreotiid - süstelahus - 50mcg 1ml 1ml 5tk